AR024746A1 - Androgenos oralmente activos. - Google Patents

Androgenos oralmente activos.

Info

Publication number
AR024746A1
AR024746A1 ARP000103625A ARP000103625A AR024746A1 AR 024746 A1 AR024746 A1 AR 024746A1 AR P000103625 A ARP000103625 A AR P000103625A AR P000103625 A ARP000103625 A AR P000103625A AR 024746 A1 AR024746 A1 AR 024746A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
oralally
active androgens
acyl
Prior art date
Application number
ARP000103625A
Other languages
English (en)
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of AR024746A1 publication Critical patent/AR024746A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Nuevos androgenos oralmente activos son derivados de delta14-nandrolona 7alfa-sustituidos. Los compuestos satisfacen la formula general 1 donde R1 es O,(H, H), (H, OR), NOR, siendo R hidrogeno, (C1-6)alquilo o (C1-.6)acilo; R2 se selecciona delgrupo consistente en (C2-4)alquilo, (C2-4)alquenilo o(C2-4)alquinilo, cada uno opcionalmente sustituido por halogeno; o R2 es ciclopropilo o ciclopropenilo, cada uno opcionalmente sustituido por (C1-2)alquilo ohalogeno; R3 es hidrogeno,(C1-2)alquilo o e tenilo; R4 es (C1-2) alquilo; R5 es hidrogeno o (C1-15)acilo; y las líneas de puntos indican enlaces opcionales.
ARP000103625A 1999-07-16 2000-07-14 Androgenos oralmente activos. AR024746A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99202348 1999-07-16

Publications (1)

Publication Number Publication Date
AR024746A1 true AR024746A1 (es) 2002-10-23

Family

ID=8240463

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103625A AR024746A1 (es) 1999-07-16 2000-07-14 Androgenos oralmente activos.

Country Status (28)

Country Link
US (3) US6313108B1 (es)
EP (1) EP1203011B1 (es)
JP (1) JP2003505394A (es)
KR (1) KR20020092890A (es)
CN (1) CN1360589A (es)
AR (1) AR024746A1 (es)
AT (1) ATE257159T1 (es)
AU (1) AU770412B2 (es)
BR (1) BR0012489A (es)
CA (1) CA2379223A1 (es)
CO (1) CO5200765A1 (es)
CZ (1) CZ2002192A3 (es)
DE (1) DE60007530T2 (es)
ES (1) ES2213596T3 (es)
HK (1) HK1043797A1 (es)
HU (1) HUP0201952A3 (es)
IL (1) IL147332A0 (es)
MX (1) MXPA02000601A (es)
NO (1) NO20020222L (es)
NZ (1) NZ516525A (es)
PE (1) PE20010330A1 (es)
PL (1) PL353007A1 (es)
RU (1) RU2002103883A (es)
SK (1) SK712002A3 (es)
TR (1) TR200200076T2 (es)
TW (1) TW548277B (es)
WO (1) WO2001005806A1 (es)
ZA (1) ZA200200106B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60004377T2 (de) * 1999-04-06 2004-06-09 Akzo Nobel N.V. Oral wirksame 7-alpha-alkyl androgene
WO2003045398A1 (en) * 2001-03-30 2003-06-05 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of making and pharmaceutical formulations comprising 7alpha, 11beta-dimethy-17beta-hydroxyestra-4, 14-dien-3-one and 17 esters thereof
US20030069215A1 (en) * 2001-03-30 2003-04-10 The Government Of The United States Of America, Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate
AU4966101A (en) * 2000-03-31 2001-10-15 Us Gov Health & Human Serv Methods of making and using 7alpha,11beta-dimethyl-17beta-hydroxy-4-estren-3-one17beta-trans-4-m-butylcyclohexane carboxylate and 7alpha,11beta-dimethyl-17beta -hydroxyestr-4-en-3-one 17-undecanoate
ES2241854T3 (es) * 2000-07-28 2005-11-01 Akzo Nobel N.V. Estrogenos de sustitucion metilo o etilo en posicion 16 alfa.
KR100937179B1 (ko) * 2002-01-21 2010-01-19 엔.브이.오가논 7α-메틸스테로이드의 제조방법
GB0304927D0 (en) * 2003-03-04 2003-04-09 Resolution Chemicals Ltd Process for the production of tibolone
PE20050677A1 (es) 2003-12-22 2005-10-04 Akzo Nobel Nv Esteroides con perfil androgenico y progestagenico mixto
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
WO2010043404A1 (en) * 2008-10-15 2010-04-22 Synthon B.V. Processes and intermediates for the production of fulvestrant
CA2835979C (en) * 2011-06-01 2018-05-01 Estetra S.A. Process for the production of estetrol intermediates
KR101994805B1 (ko) 2011-06-01 2019-07-01 에스테트라 에스.피.알.엘. 에스테트롤 중간체의 제조 방법
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
CN103890001B (zh) * 2011-10-07 2016-05-04 埃斯特拉有限责任公司 用于制备雌四醇的方法
WO2015181116A1 (en) 2014-05-26 2015-12-03 Crystal Pharma, S.A.U. Process and intermediades for the preparation of 7-alkylated steroids
JP6866561B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロールを含有する口腔内崩壊錠
RS60252B1 (sr) 2015-06-18 2020-06-30 Estetra Sprl Orodisperzibilna dozna jedinica koja sadrži komponentu estetrola
CN107750157B (zh) 2015-06-18 2021-07-13 埃斯特拉私人有限责任公司 含雌四醇的口腔分散片剂
PL3106148T3 (pl) 2015-06-18 2018-08-31 Mithra Pharmaceuticals S A Jednostka dawkowania ulegająca rozpadowi w jamie ustnej zawierająca składnik estetrolowy
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
CN116693587A (zh) * 2017-02-23 2023-09-05 美国西门子医学诊断股份有限公司 化学发光雄烯二酮缀合物
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA712312B (en) * 1970-04-28 1972-01-26 Ochsner Med Found Alton 4,14-estradiene compounds

Also Published As

Publication number Publication date
MXPA02000601A (es) 2002-07-30
NO20020222L (no) 2002-01-25
DE60007530D1 (de) 2004-02-05
EP1203011A1 (en) 2002-05-08
EP1203011B1 (en) 2004-01-02
CN1360589A (zh) 2002-07-24
NO20020222D0 (no) 2002-01-15
PE20010330A1 (es) 2001-03-22
AU6562900A (en) 2001-02-05
KR20020092890A (ko) 2002-12-12
US20020022609A1 (en) 2002-02-21
US6780854B2 (en) 2004-08-24
US20030087886A1 (en) 2003-05-08
BR0012489A (pt) 2002-04-02
US6541465B2 (en) 2003-04-01
HUP0201952A2 (en) 2002-10-28
ES2213596T3 (es) 2004-09-01
HK1043797A1 (zh) 2002-09-27
IL147332A0 (en) 2002-08-14
JP2003505394A (ja) 2003-02-12
TW548277B (en) 2003-08-21
NZ516525A (en) 2003-06-30
TR200200076T2 (tr) 2002-04-22
CO5200765A1 (es) 2002-09-27
SK712002A3 (en) 2002-06-04
PL353007A1 (en) 2003-09-22
CA2379223A1 (en) 2001-01-25
CZ2002192A3 (cs) 2002-06-12
AU770412B2 (en) 2004-02-19
DE60007530T2 (de) 2004-12-23
US6313108B1 (en) 2001-11-06
RU2002103883A (ru) 2004-02-27
ZA200200106B (en) 2003-06-25
WO2001005806A1 (en) 2001-01-25
HUP0201952A3 (en) 2003-10-28
ATE257159T1 (de) 2004-01-15

Similar Documents

Publication Publication Date Title
AR024746A1 (es) Androgenos oralmente activos.
DK1177176T3 (da) Triarylsyrederivater som PPAR-receptorligander
DE69724777D1 (de) Pentafluorobenzensulfonamiden und analoge
DK1382604T3 (da) Quinolinderivater med en azolylgruppe og quinazolinderivater
NO20023823D0 (no) Fremgangsmåte for tilvirkning og bruk av pyrrolopyrimidinon- derivater
ES2269465T3 (es) Compuestos heterociclicos de union a los receptores de la quimioquina.
DE122010000035I2 (de) Substituierte thien-3-yl-sulfonylamino(thio)carbonyl-triazolin(thi)one
DK1489090T3 (da) Hidtil ukendte pseudoerythromycinderivater
PT1007523E (pt) Derivados indole e 2,3-di-ridroindole, sua preparacao e utilizacao
CY1111816T1 (el) Παραγωγο θειαδιαζολινης για την θεραπεια του καρκινου
BRPI0409376A (pt) derivados de indeno como agentes farmacêuticos
DK0882726T3 (da) Carbazolcarboxamider som 5-HT1F-agonister
ES496451A0 (es) Un procedimiento para la produccion de derivados de 1,2,3,4,5,6-hexahidro-6-fenil-azepino (4,5,b) indol.
PL335012A1 (en) Novel derivatives of indan-1-ole, method of obtaining and composition containing them
CO5160345A1 (es) Nuevos androgenos oralmente activos derivados de 7 alfa- metil-19-nortestosterona
ECSP003572A (es) Androgenos oralmente activos
ES2195500T3 (es) Dereivados del 2-indanometanol y su utilizacion a titulo de ingredientes perfumantes.
MY139258A (en) Carbamoyl-type benzofuran derivatives
AR024797A1 (es) Forma cristalina iii de la n-(4-(5-dimetilaminonaftalen-1-sulfonilamino)fenil)-3-hidroxi-2,2-dimetilpropionamida
ECSP003416A (es) Nuevos androgenos oralmente activos derivados de 7beta- metil-19- nortestosterona
DE69624459D1 (de) Kondensierte indan-derivate und ihre salze
TR200100475T2 (tr) N-İkameli azabisikloheptan türevlerinin üretimleri ve kullanımları.
DE60237652D1 (de) Variolinderivate und ihre Verwendung als Cytostatika
DE69828087D1 (de) Aminderivate
AR019894A1 (es) Empleo de un derivado de tetrahidroxipiridina (0 4-hidroxipiridina) butilazol

Legal Events

Date Code Title Description
FA Abandonment or withdrawal